Development of a live attenuated varicella vaccine.
The Oka strain of varicella virus, isolated in our labolatory, was serially cultivated in guinea-pig embryo cultures (GPEC), and a considerable amount of cell-free virus was obtained from infected cell. GPEC passage virus at the 6th passage level was used in a small scale field trial. Susceptible children of 1 to 10 years old were injected subcutaneously with 100 to 1,000 PFU of virus. No clinical reactions due to the vaccination were observed in any children, and a high rate of antibody response was obtained with viral doses of more than 200 PFU. Attenuated virus obtained by passage in GPEC was propagated in human diploid (WI-38) cells, and it was also effective in inducing an immune response without clinical reactions. The results show that the Oka strain of varicella virus passaged in GPEC and human diploid (WI-38) cells may be used safely and effectively as a live attenuated vaccine.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D003168:Complement Fixation Tests; D004171:Diploidy; D004622:Embryo, Mammalian; D005260:Female; D005455:Fluorescent Antibody Technique; D006168:Guinea Pigs; D014645:Herpesvirus 3, Human / Q000276:immunology* / Q000472:pathogenicity; D006801:Humans; D007223:Infant; D007279:Injections, Subcutaneous; D008168:Lung; D008297:Male; D008722:Methods; D009500:Neutralization Tests; D014611:Vaccination; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; D014774:Virulence
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines